Refractory Angina - Pipeline Insight, 2021
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Refractory Angina - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Refractory Angina pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Refractory Angina: Overview
Refractory angina (RA) is conventionally defined as a chronic condition (?3 months in duration) characterised by angina in the setting of coronary artery disease (CAD), which cannot be controlled by a combination of optimal medical therapy, angioplasty or bypass surgery, and where reversible myocardial ischaemia has been clinically established to be the cause of the symptoms. There is a sensation of pressure or pain in the chest that is the result of insufficient blood flow to the heart muscle and in which treatment with medication and heart surgery is either insufficient or no longer effective. Patients have reproducible lifestyle-limiting symptoms of chest pain, shortness of breath, and easy fatigability. These symptoms are often due to totally occluded coronary arteries or diffuse coronary atherosclerosis that makes revascularization problematic.
'Refractory Angina - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Refractory Angina pipeline landscape is provided which includes the disease overview and Refractory Angina treatment guidelines. The assessment part of the report embraces, in depth Refractory Angina commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Refractory Angina collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Refractory Angina report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Refractory Angina Emerging Drugs
Further product details are provided in the report……..
Refractory Angina: Therapeutic Assessment
This segment of the report provides insights about the different Refractory Angina drugs segregated based on following parameters that define the scope of the report, such as:
Refractory Angina: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Refractory Angina therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Refractory Angina drugs.
Refractory Angina Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Refractory Angina - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Refractory Angina pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Refractory Angina: Overview
Refractory angina (RA) is conventionally defined as a chronic condition (?3 months in duration) characterised by angina in the setting of coronary artery disease (CAD), which cannot be controlled by a combination of optimal medical therapy, angioplasty or bypass surgery, and where reversible myocardial ischaemia has been clinically established to be the cause of the symptoms. There is a sensation of pressure or pain in the chest that is the result of insufficient blood flow to the heart muscle and in which treatment with medication and heart surgery is either insufficient or no longer effective. Patients have reproducible lifestyle-limiting symptoms of chest pain, shortness of breath, and easy fatigability. These symptoms are often due to totally occluded coronary arteries or diffuse coronary atherosclerosis that makes revascularization problematic.
'Refractory Angina - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Refractory Angina pipeline landscape is provided which includes the disease overview and Refractory Angina treatment guidelines. The assessment part of the report embraces, in depth Refractory Angina commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Refractory Angina collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Refractory Angina R&D. The therapies under development are focused on novel approaches to treat/improve Refractory Angina.
This segment of the Refractory Angina report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Refractory Angina Emerging Drugs
- XC001: XyloCor Therapeutics
- IMB-101: Imbria pharmaceticals
Further product details are provided in the report……..
Refractory Angina: Therapeutic Assessment
This segment of the report provides insights about the different Refractory Angina drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Refractory Angina
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Refractory Angina: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Refractory Angina therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Refractory Angina drugs.
Refractory Angina Report Insights
- Refractory Angina Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Refractory Angina drugs?
- How many Refractory Angina drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Refractory Angina?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Refractory Angina therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Refractory Angina and their status?
- What are the key designations that have been granted to the emerging drugs?
- XyloCor Therapeutics
- Imbria pharmaceticals
- Angionetics Inc.
- XC001
- IMB-101
- Ad5FGF-4
Introduction
Executive Summary
Refractory Angina: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Mid Stage Products (Phase II)
Comparative Analysis
IMB-101: Imbria Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
XC001: XyloCor Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Refractory Angina Key Companies
Refractory Angina Key Products
Refractory Angina- Unmet Needs
Refractory Angina- Market Drivers and Barriers
Refractory Angina- Future Perspectives and Conclusion
Refractory Angina Analyst Views
Refractory Angina Key Companies
Appendix
Executive Summary
Refractory Angina: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Mid Stage Products (Phase II)
Comparative Analysis
IMB-101: Imbria Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
XC001: XyloCor Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Refractory Angina Key Companies
Refractory Angina Key Products
Refractory Angina- Unmet Needs
Refractory Angina- Market Drivers and Barriers
Refractory Angina- Future Perspectives and Conclusion
Refractory Angina Analyst Views
Refractory Angina Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Refractory Angina
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Refractory Angina
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Refractory Angina
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Refractory Angina
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
